NEW YORK, NY / ACCESS Newswire / March 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...
Wednesday’s 10 Top Performers. In this article, we are going to take a look at where Sarepta Therapeutics Inc. (NASDAQ:SRPT) ...
It was a busy week in the biotech sector with important regulatory and pipeline updates. Among these, Sarepta Therapeutics ...
Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 24.9% in the pre-market session after the company reported ...
Sarepta Therapeutics shares dropped 20% after a patient's death raises Elevidys safety concerns. Read why I am downgrading ...
The company said that more than 800 people have been treated with Elevidys, with only one experiencing liver failure.
HighTower Advisors LLC decreased its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 6.5% during the ...
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “buy” rating reissued by equities research analysts at ...
Stock futures slipped in premarket trading on Tuesday, while Treasury yields rose as investors braced for the Federal Reserve ...
Crispr Therapeutics (CRSP), and Sarepta Therapeutics (SRPT) shares are lower in relation to a gene therapy death ...
Stay updated on market trends for SRPT. Arrowhead Pharmaceuticals Stock Falls After Early-Stage Data From RNA-Based Therapeutic For Kidney Diseases Arrowhead's ARO-C3 cut C3 levels by up to 89% ...